# Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain

> **NCT03281200** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 172 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** L - Antineoplastic and immunomodulating agents
- **DRUG:** L01 - Antineoplastic agents
- **DRUG:** L01X - Other antineoplastic agents
- **DRUG:** L01XE - Protein kinase inhibitors
- **DRUG:** L01XE31 - Nintedanib

## Key facts

- **NCT ID:** NCT03281200
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-24
- **Primary completion:** 2018-06-07
- **Final completion:** 2018-06-07
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2019-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03281200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03281200, "Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03281200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*